Bamlanivimab and etesevimab combination has been authorised under Emergency Use Authorisation in the US and select EU countries for the treatment of the disease.
New Delhi [India], June 1 (ANI): Eli Lilly and Company India said on Tuesday it has received permission for restricted emergency use of its antibody drugs bamlanivimab 700 mg and etesevimab 1,400 mg in India for treatment of patients with mild to moderate coronavirus disease 2019 (Covid-19).